Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT01175486

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01175486
Other papers using this trial's data
  • Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study PloS one, 2016 DOI, PubMed 27812149, PMC5094682 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01175486. Randomized; no masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy
Condition
Diabetes
Intervention (Drug)
Actos (Pioglitazone)
Intervention (Drug)
Acarbose
Lead sponsor
Taipei Veterans General Hospital, Taiwan (class: other government)

Record details

Record id
cardio:ct-nct01175486
Content hash
1cb76793354a42c4645868aa291dfacbe20595fdc3bfef671e7e902d3318d99b